A new study looking at a dual antithrombotic strategy in patients with atrial fibrillation after PCI has bolstered evidence supporting a move away from standard triple therapy with warfarin. The RE-DUAL PCI study presented at the ESC this week and simultaneously published in the NEJM showed that combining one of two dabigatran (Pradaxa) doses with ...
Dual therapy non inferior to triple therapy in AF after PCI
By Sunalie Silva
31 Aug 2017